Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- Submitting institution
-
The University of Hull
- Unit of assessment
- 3 - Allied Health Professions, Dentistry, Nursing and Pharmacy
- Output identifier
- 1989003
- Type
- D - Journal article
- DOI
-
10.1016/s2213-8587%2819%2930192-5
- Title of journal
- Lancet Diabetes and Endocrinology
- Article number
- -
- First page
- 515
- Volume
- 7
- Issue
- 7
- ISSN
- 2213-8587
- Open access status
- Compliant
- Month of publication
- June
- Year of publication
- 2019
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
115
- Research group(s)
-
-
- Citation count
- 49
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The author made a substantial contribution either to the conception and design of the study.
AND
The author critiqued the output for important intellectual content.
- Non-English
- No
- English abstract
- -
